Premier Alternatives

Life Biosciences

Boston, MA · Founded 2017 · Privately Held (backing)

Developer of drug therapies designed to improve the lives of people as they age. Life Biosciences is based in Boston, MA and was founded in 2017. Its last reported valuation was $500 million in Jan 2019. It has raised $255 million across 3 recorded rounds; the latest was a $31 million early-stage round in Nov 2025.

Last reported valuation
$500.0M
Oct 2026
Priced at
—
Total raised
$255.2M
Last round
Early Stage VC
Nov 2025

Life Biosciences key facts

as of Oct 2026
  • Developer of drug therapies designed to improve the lives of people as they age.
  • Life Biosciences is valued at approximately $500.0M as of Oct 2026 (last reported valuation).
  • It has raised $255.2M across 3 recorded rounds; the latest was Early Stage VC ($31.0M) in Nov 2025.
  • Notable investors include Gaingels, Alpha Wave Global, The Venture Collective, LeFrak, Globalive Capital — 16 tracked in total.
  • Life Biosciences has filed 4 Form Ds with the SEC since 2019, most recently Jun 2021 ($74.8M sold to 35 investors).
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$500.0M

Life Biosciences's last reported valuation, Jan 2019. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of Life Biosciences with a free account
  • ·The complete investor list: 16 names
  • ·Watch Life Biosciences: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Life Biosciences funding rounds

3 rounds
Nov 2025Early Stage VC$31.0MSEC filing▮
May 2020Later Stage VC$74.8MSEC filing▮
Aug 2018Early Stage VC$48.6MSEC filing▮
Full funding history →

Life Biosciences valuation

Life Biosciences's last reported valuation was $500 million in Jan 2019. No priced round, secondary trade or fund mark has surfaced since.

How much has Life Biosciences raised?

Life Biosciences has raised $255 million across 3 recorded rounds since 2018. The largest was a $74.8 million later-stage round in May 2020; the most recent was a $31 million early-stage round in Nov 2025.

Life Biosciences has filed 4 Form Ds with the SEC since 2019, most recently in Jun 2021 ($74.8 million sold to 35 investors).

Life Biosciences investors

16 investors are on record for Life Biosciences, including Gaingels, Alpha Wave Global, The Venture Collective and LeFrak. By type, the record holds 4 venture capital firms, 1 family office and 1 growth equity firm. The early-stage round in Nov 2025 drew 8 investors.

About Life Biosciences

Developer of drug therapies designed to improve the lives of people as they age. The company's drugs help to combat the eight pathways of age-related decline, and its work addresses health decline due to aging as a systemic breakdown of the body, rather than a series of isolated events and conditions, enabling senior citizens to tackle age-related diseases to extend healthy life spans.

Sector
Healthcare
HQ
Boston, MA, United States
Founded
2017
Employees
26
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.